Browsing Tag

CytoDyns

CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at…

Editor Dec 1, 2021

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Firm"), a late-stage biotechnology firm growing Leronlimab, a CCR5 antagonist with potential for a number of therapeutic indications, reminded buyers that Dr. Scott Kelly,…

Food and Drinks

CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at World…

Editor Dec 1, 2021

Get instantaneous notifications when there may be information about your shares. Request your one-week free trial of StreetInsider Premium right here. VANCOUVER, Wash. - (BUSINESS WIRE) - CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or…

Food and Drinks

CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at World…

Editor Nov 30, 2021

VANCOUVER, Wash. - (BUSINESS WIRE) - Nov. November 2021--CytoDyn Inc.…

Lifestyle

CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at World…

Editor Nov 29, 2021

VANCOUVER, Wash. - (BUSINESS WIRE) - Nov. November 2021--CytoDyn Inc.…

Lifestyle

CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at the…

Editor Sep 24, 2021

Food and Drinks

CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at the World…

Editor Sep 21, 2021

Lifestyle

CytoDyn’s Chief Medical Officer Dr. Scott Kelly to Present at Triple Negative Breast Cancer Drug…

Editor Aug 18, 2021

VANCOUVER, Wash., April 27, 2021 (GLOBE NEWSWIRE) - CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Firm"), a late-stage biotechnology firm creating Leronlimab (Vyrologix or PRO 140), a CCR5 antagonist with potential for a number of…

Lifestyle

CytoDyn’s Chief Medical Officer Dr. Scott Kelly to Present

Editor Aug 4, 2021

VANCOUVER, Wash., April 27, 2021 (GLOBE NEWSWIRE) - CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Firm"), a late-stage biotechnology firm growing Leronlimab (Vyrologix or PRO 140), a CCR5 antagonist with potential for a number of…

Lifestyle

CytoDyn’s COVID-19 Long-Hauler’s Trial Closed as Enrollment

Editor Jul 29, 2021

VANCOUVER, Wash., April 8, 2021 (GLOBE NEWSWIRE) - CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Firm"), a late-stage biotechnology firm creating Leronlimab (PRO 140), a CCR5 antagonist with potential a number of therapeutic…

Lifestyle

CytoDyn’s Leronlimab Featured on OneNews in Philippines on

Editor Jun 29, 2021

Drs. Pourhassan, Recknor, Seethamraju and Nicolas will carry out in a one-hour section beginning at 5:00 p.m. PT / 8:00 p.m. ET on Sunday, Might ninth VANCOUVER, Wash., Might 7, 2021 (GLOBE NEWSWIRE) - CytoDyn Inc. (OTC.QB: CYDY),…